nVector, Inc.

SCOTTSDALE, AZ · CIK 0001936729 · Biotech · Private

Platform for discovering and developing central nervous system therapeutics

nvector.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$125K
1 Form D · Jul 2022
51 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$125,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2653TARTAN LLC—$130K
2654NEUIMMUNE, INC.—$125K
2655RESTORE THERAPEUTICS LLC——
2656nVector, Inc.—$125K
2657Sustained Therapeutics Inc.—$100K
2658GALIBRA NEUROSCIENCE, INC.—$100K
2659Blue Marlin Therapeutics, Inc.—$100K

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 3 related persons
  • Robert BowserDirector · Executive Officer
  • Michael HullExecutive Officer
  • Frederic ManfredssonExecutive Officer

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.